Following publication of the Short Communication by Shafi Mahmud, Abdo A Elfiky, Al Amin, Sumon Chandro Mohanto, Ekhtiar Rahman, Uzzal Kumar Acharjee & Abu Saleh, ‘Targeting SARS-CoV-2 nonstructural protein 15 endoribonuclease: an in silico perspective’, which appeared in the July 2021 issue of Future Virology 16(7), 475–489 (2021), it has been brought to our attention that there was an error regarding the phrase “in the active site” and “into the active site”.
This has now been corrected as follows:
In the Abstract, the phrase “Moreover, saquinavir and aprepitant make nonbonded interactions with Leu201 in the active site cavity of Nsp15, while the drug valrubicin interacts with Arg199 and Leu201” has been corrected to “Moreover, saquinavir and aprepitant make nonbonded interactions with Leu201 near the active site cavity of Nsp15, while the drug valrubicin interacts with Arg199 and Leu201”
In the Results, the phrase “Table 1 lists the formed interactions established upon docking the best three drugs (saquinavir, valrubicin and aprepitant) into SARS-CoV-2 Nsp15 active site” has been corrected to “Table 1 lists the formed interactions established upon docking the best three drugs (saquinavir, valrubicin and aprepitant) near the SARS-CoV-2 Nsp15 active site”
The legend of Table 1, “Interactions established upon docking the drugs saquinair, valrubicin and aprepitant into the active site of SARS-CoV-2 nonstructural protein 15.” Has been corrected to “Interactions established upon docking the drugs saquinair, valrubicin and aprepitant near the active site of SARS-CoV-2 nonstructural protein 15.”
In the Discussion, the phrase “Moreover, the binding of these three drug molecules in the active sites of Nsp15 may contradict viral infection.” has been corrected to “Moreover, the binding of these three drug molecules near the active sites of Nsp15 may contradict viral infection.”
The authors and editors of Future Virology would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.